Cancer Research

Bio-Path Projects High Growth Potential for Investors

Bio-Path Holdings Inc., (OTCQX: BPTH) (“Bio-Path”), a research and development company for cancer treatment, recently announced that its first two initial drug candidates have a market potential of more than $4 billion. With its recent value set at $0.35 a share and currently rising with a $22 million market cap, Bio-Path officials state they are poised for significant growth in 2013. Continue reading →